Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 11/20 | 0.59 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12443663 | 1.00 | MAPKAPK5 (0.59) | MAPKAPK5BTKSYKMAPTLRRK2 | |
| SCHEMBL2218239 | 1.00 | MAPKAPK5 (0.59) | MAPKAPK5BTKSYKMAPTLRRK2 | |
| SCHEMBL1476125 | 0.87 | MAPKAPK5 (0.75) | MAPKAPK5SYKEML4ALK | |
| SCHEMBL1476556 | 0.86 | MAPKAPK5 (0.64) | MAPKAPK5SYKALK | |
| SCHEMBL12443271 | 0.85 | MAPKAPK5 (0.65) | MAPKAPK5SYK | |
| SCHEMBL2217160 | 0.84 | MAPKAPK5 (0.63) | MAPKAPK5SYK | |
| SCHEMBL12515799 | 0.84 | MAPKAPK5 (0.51) | MAPKAPK5SYK | |
| SCHEMBL2219877 | 0.84 | MAPKAPK5 (0.51) | MAPKAPK5SYK | |
| SCHEMBL1476500 | 0.84 | MAPKAPK5 (0.61) | MAPKAPK5SYKALK | |
| SCHEMBL1475848 | 0.82 | MAPKAPK5 (0.59) | MAPKAPK5SYKEML4ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | PTGES, IL1B, PTGER1 | MAPKAPK5 5/4885BTK 4417/4885SYK 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.